Cargando…

Novel vaccine safety issues and areas that would benefit from further research

Vaccine licensure requires a very high safety standard and vaccines routinely used are very safe. Vaccine safety monitoring prelicensure and postlicensure enables continual assessment to ensure the benefits outweigh the risks and, when safety problems arise, they are quickly identified, characterise...

Descripción completa

Detalles Bibliográficos
Autores principales: Salmon, Daniel A, Lambert, Paul Henri, Nohynek, Hanna M, Gee, Julianne, Parashar, Umesh D, Tate, Jacqueline E, Wilder-Smith, Annelies, Hartigan-Go, Kenneth Y, Smith, Peter G, Zuber, Patrick Louis F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137224/
https://www.ncbi.nlm.nih.gov/pubmed/34011502
http://dx.doi.org/10.1136/bmjgh-2020-003814
_version_ 1783695578835714048
author Salmon, Daniel A
Lambert, Paul Henri
Nohynek, Hanna M
Gee, Julianne
Parashar, Umesh D
Tate, Jacqueline E
Wilder-Smith, Annelies
Hartigan-Go, Kenneth Y
Smith, Peter G
Zuber, Patrick Louis F
author_facet Salmon, Daniel A
Lambert, Paul Henri
Nohynek, Hanna M
Gee, Julianne
Parashar, Umesh D
Tate, Jacqueline E
Wilder-Smith, Annelies
Hartigan-Go, Kenneth Y
Smith, Peter G
Zuber, Patrick Louis F
author_sort Salmon, Daniel A
collection PubMed
description Vaccine licensure requires a very high safety standard and vaccines routinely used are very safe. Vaccine safety monitoring prelicensure and postlicensure enables continual assessment to ensure the benefits outweigh the risks and, when safety problems arise, they are quickly identified, characterised and further problems prevented when possible. We review five vaccine safety case studies: (1) dengue vaccine and enhanced dengue disease, (2) pandemic influenza vaccine and narcolepsy, (3) rotavirus vaccine and intussusception, (4) human papillomavirus vaccine and postural orthostatic tachycardia syndrome and complex regional pain syndrome, and (5) RTS, S/adjuvant system 01 malaria vaccine and meningitis, cerebral malaria, female mortality and rebound severe malaria. These case studies were selected because they are recent and varied in the vaccine safety challenges they elucidate. Bringing these case studies together, we develop lessons learned that can be useful for addressing some of the potential safety issues that will inevitably arise with new vaccines.
format Online
Article
Text
id pubmed-8137224
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-81372242021-06-01 Novel vaccine safety issues and areas that would benefit from further research Salmon, Daniel A Lambert, Paul Henri Nohynek, Hanna M Gee, Julianne Parashar, Umesh D Tate, Jacqueline E Wilder-Smith, Annelies Hartigan-Go, Kenneth Y Smith, Peter G Zuber, Patrick Louis F BMJ Glob Health Analysis Vaccine licensure requires a very high safety standard and vaccines routinely used are very safe. Vaccine safety monitoring prelicensure and postlicensure enables continual assessment to ensure the benefits outweigh the risks and, when safety problems arise, they are quickly identified, characterised and further problems prevented when possible. We review five vaccine safety case studies: (1) dengue vaccine and enhanced dengue disease, (2) pandemic influenza vaccine and narcolepsy, (3) rotavirus vaccine and intussusception, (4) human papillomavirus vaccine and postural orthostatic tachycardia syndrome and complex regional pain syndrome, and (5) RTS, S/adjuvant system 01 malaria vaccine and meningitis, cerebral malaria, female mortality and rebound severe malaria. These case studies were selected because they are recent and varied in the vaccine safety challenges they elucidate. Bringing these case studies together, we develop lessons learned that can be useful for addressing some of the potential safety issues that will inevitably arise with new vaccines. BMJ Publishing Group 2021-05-19 /pmc/articles/PMC8137224/ /pubmed/34011502 http://dx.doi.org/10.1136/bmjgh-2020-003814 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Analysis
Salmon, Daniel A
Lambert, Paul Henri
Nohynek, Hanna M
Gee, Julianne
Parashar, Umesh D
Tate, Jacqueline E
Wilder-Smith, Annelies
Hartigan-Go, Kenneth Y
Smith, Peter G
Zuber, Patrick Louis F
Novel vaccine safety issues and areas that would benefit from further research
title Novel vaccine safety issues and areas that would benefit from further research
title_full Novel vaccine safety issues and areas that would benefit from further research
title_fullStr Novel vaccine safety issues and areas that would benefit from further research
title_full_unstemmed Novel vaccine safety issues and areas that would benefit from further research
title_short Novel vaccine safety issues and areas that would benefit from further research
title_sort novel vaccine safety issues and areas that would benefit from further research
topic Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137224/
https://www.ncbi.nlm.nih.gov/pubmed/34011502
http://dx.doi.org/10.1136/bmjgh-2020-003814
work_keys_str_mv AT salmondaniela novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch
AT lambertpaulhenri novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch
AT nohynekhannam novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch
AT geejulianne novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch
AT parasharumeshd novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch
AT tatejacquelinee novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch
AT wildersmithannelies novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch
AT hartigangokennethy novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch
AT smithpeterg novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch
AT zuberpatricklouisf novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch